Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05718375Phase 2Completed

Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Role: lead

NCT07459829Phase 2Not Yet Recruiting

Study of CU06-1004 in Patients With Daibetic Macular Edema

Role: lead

NCT05573100Phase 2Completed

The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)

Role: lead

NCT05907330Phase 2Not Yet Recruiting

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

Role: lead

NCT04795037Phase 1Completed

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Role: lead

All 5 trials loaded